Infectious disease
Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization for its COVID-19 vaccine by May.
What percentage of a population needs to be immune in order to achieve herd immunity is a matter of debate among scientists and public health officials.
The company has agreed to deliver 100 million doses of the vaccines by the end of June.
It was another busy week for clinical trial news. Here’s a look.
As the vaccines against COVID-19 are being rolled out worldwide, numerous studies are being conducted to evaluate how the vaccines do under less controlled situations. Here’s a look.
As scientists and vaccine manufacturers continue to test their products against the variants, researchers are seeing new variants cropping up that originated in the U.S.
The date set by the FDA’s independent advisors for debating that decision is Friday, February 26.
Even with its potential technical advantages, Novavax has some challenges.
Although problems with actually getting shots into arms have been described thoroughly, manufacturing problems and scale-up haven’t been the focus of much reporting.
Chinese fusion protein company Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push its COVID-19 vaccine into Phase II/III testing and production planning.
PRESS RELEASES